Simvastatin in sight threatening Uveitis trial (SU)
Research type
Research Study
Full title
Can simvastatin significantly reduce the amount of immunosuppressive medication required by patients with sight threatening uveitis? A phase IIb, single site, randomized, placebo controlled, double blinded trial.
IRAS ID
156966
Contact name
Sue Lightman
Contact email
Sponsor organisation
UCL, Joint Research Office
Eudract number
2014-003119-13
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 7 months, 31 days
Research summary
This study aims to examine the immunosupressive effect of oral simvastatin 80mg once a day among patients with uveitis who are receiving systemic corticosteroids. Recently it has been found that simvastatin has an immunosupressive effect in humans, results in greater control of systemic inflammation and slows the progression of conditions such as multiple sclerosis.
This study will be conducted at Moorfields Eye Hospital and will include patients with uveitis who require systemic corticosteroids to control their ocular inflammation. Patients will be randomised to either receive either simvastatin or placebo, in addition to their immunosuppression treatment.
The study will follow these patients for 24 months and explore whether the addition of simvastatin results in a greater tapering in systemic corticosteroids than placebo.REC name
London - Bloomsbury Research Ethics Committee
REC reference
15/LO/0084
Date of REC Opinion
11 Feb 2015
REC opinion
Favourable Opinion